Finally, establish realistic timelines for metabolic improvements, recognizing that benefits typically emerge gradually over several months of treatment
Medical Eligibility Criteria BMI Requirements (Same as In-Person): You qualify if: BMI 30 (obesity category), OR BMI 27 (overweight category) with at least one weight-related health condition Weight-Related Conditions: Type 2 diabetes or prediabetes Hypertension (high blood pressure) High cholesterol or dyslipidemia Obstructive sleep apnea Cardiovascular disease Polycystic ovary syndrome (PCOS) Non-alcoholic fatty liver disease Osteoarthritis worsened by weight Calculate Your BMI: BMI = (Weight in pounds / Height in inches) 703 Quick Reference: Age Requirements: Typically 18+ for adults Some medications approved for age 12+ (with parental consent) Contraindications (Cannot Prescribe If Present): Absolute Contraindications: Personal or family history of medullary thyroid carcinoma (MTC) Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) Pregnancy or planning pregnancy within 2 months Breastfeeding Previous severe allergic reaction to GLP-1 medications Relative Contraindications (May Preclude or Require Caution): History of pancreatitis Severe gastroparesis Active eating disorder (anorexia, bulimia) Severe kidney disease Active gallbladder disease Diabetic retinopathy (recent diagnosis) Medication Considerations May Require Dose Adjustments: Currently taking insulin On sulfonylureas (diabetes medications) Taking blood thinners (warfarin) Generally Compatible: Blood pressure medications Cholesterol medications Most antidepressants Thyroid medications Provider will review all current medications during consultation
Fermentable fibers that are found in food like Brussels sprouts, black beans, lentils, split peas, oats, and raspberries enhance GLP-1 release to aid in blood sugar control and optimal gut function
Superior weight loss with semaglutide 2.4 mg compared with placebo as adjunct to intensive behavioral therapy in adults with obesity: The STEP 3 randomized clinical trial
[18] MS patients experiencing worsening neurological symptoms during semaglutide therapy require prompt evaluation to distinguish medication effects from MS disease activity, though the latter is far more likely
.webp)
